Geert-Jan Mulder, MD, co-founded Forbion in 2006 and currently serves on the Board of several Forbion portfolio companies. In addition, Geert-Jan led the firm’s successful investment in bluebirdbio (NASDAQ: BLUE), which went public in 2013, where he supported the company in clinical development and served as the chairman for several years. Other investments include Acorda Therapeutics (NASDAQ:ACOR), which went public in 2006 where he was part of the AMPYRA^® (dalfampridine) board panel to evaluate a new clinical endpoint in Multiple Sclerosis; PanGenetics B.V. which sold to Abbott, where he led the Series B financing round; and Transave, where supported the company’s clinical development for ARIKAYCE^® (liposomal amikacin for inhalation) partly as interim CMO, he also served on the Board of Directors till the merger with Insmed (NASDAQ:INSM) in 2010.

Prior to joining ABN AMRO Capital Life Sciences (Forbion’s predecessor) in 2001, Geert-Jan received his Medical Degree from the University of Utrecht (NL) and spent two years as a clinician in Obstetrics and Gynecology at the University Medical Center of Utrecht (UMC). He then joined Searle (now Pfizer) working in the field of Arthritis & Pain, involved in clinical development as well as in the European Advocacy Development for the pre-launch of Celebrex^®. After transitioning to Byk Gulden (now Takeda) he became Clinical Research Manager, where his department was responsible for the design and execution of numerous early and late stage clinical trials that formed the basis for two global product registrations, i.e. Daxas^® and Alvesco^® in the field of Respiratory Medicine (asthma and COPD). He was a member of the Global Medical Marketing group of their Respiratory Franchise and was involved in the line extension program for Pantozol^®.

Edwin de Graaf is a managing partner of Gilde Healthcare. He led Gilde’s investments in GlycArt (trade sale to Roche), IDEA (license to Alpharma Pharmaceuticals), Omegatech (trade sale to Martek Biosciences, now DSM), Pieris, Prosonix, Santaris Pharma (trade sale to Roche) and uniQure (IPO on NASDAQ). Edwin represented Gilde on the boards of Glycart, IDEA, Santaris Pharma and uniQure and currently serves on the boards of AM Pharma, Ascendis Pharma, Pieris and Prosonix.

Edwin joined Gilde as an investment manager of Gilde Strategic Situations -a fund of funds- where he was involved in investments in funds in Europe and the United States in 1997. Two years later, he joined Gilde’s health care fund. Prior to Gilde, Edwin was a tax consultant with Coopers & Lybrand (now PwC) for three years.

Edwin de Graaf holds a Master in Business and Fiscal Economics from the Erasmus University Rotterdam.

Klaus is a venture capital investor with BB Biotech Ventures at Bellevue Group. Klaus has invested in numerous emerging biotech and pharma companies, in both the US and Europe. His other current and past board assignments include Agendia BV, Alpex Pharma SA, Cadence Pharmaceuticals Inc. (now public), Glycart Biotechnology AG (acquired by Roche), Orthocon Inc., Pevion Biotech AG and Vaximm AG. Prior to joining Bellevue, Klaus was an investment manager at another European private equity firm and a business consultant with Booz, Allen & Hamilton.

Klaus received an MA in chemistry from the University of North Carolina, Chapel Hill, and a PhD in Molecular Biology from the University of Heidelberg.

Dr Guido Magni was trained as an MD with a specialization in neuropharmacology. He was previously the global head of the medical science department of Roche Pharmaceuticals, Basel, Switzerland, a post he held for 12 years. During this time he was responsible for the development and the approval of a large number of New Molecular/Biological Entities including Cellcept, Pegasys, Xeloda, Herceptin, Tamiflu, Tarceva and Mabthera. In his position as global head he defined and ensured the implementation of the overall strategies, goals and objectives of the department, with responsibility for drug development from first in human trials right through to registration and post-marketing approval. Dr Magni also is venture partner of Versant, with oversight of Versant’s European activities. Furthermore, Dr Magni serves as a board member of Nouscom, Aprea, Lava Therapeutics, Gensight Biological and Piqur. He also was a board member of Adolor Corporation, recently sold to Cubist, and Anabasis, recently sold to Dompe. Dr Magni is the author of more than 100 papers published in internationally peer reviewed journals.

Ashok has more than 20 years of international healthcare experience, focused primarily on Corporate & Business Development, Mergers & Acquisitions and Strategic Planning within leading multinational corporations where he was responsible for consummating a number of transformational deals and exits. His breadth of experience includes the unique opportunity of being involved in positions of significant influence across the sectors of functional foods, consumer health, pharmaceuticals and biotech. Additionally, he has built a considerable network that enables global access to healthcare corporations, financial and high net worth communities.

Recent appointments include Global Head of Corporate & Business Development at Serono, Senior Vice President and Global Head of Strategy and Business Development at Novartis Consumer Health, Vice President and Head of Strategy and Business Development at Baxter Europe as well as senior positions at Roche, Andersen Consulting and Rhone-Poulenc. He is currently Senior Vice President at Inventages Venture Capital and also serves as CEO and member of the board of directors at Horizon Science Pvt Ltd. Other board positions include Atonomics, Tanfield Foods, AM-Pharma and ImmBio.

Ashok holds a BA in Economics & Commerce and an MBA from ESSEC.

Rémi joined Kurma Life Science Partners in September 2010. Prior to that, he held positions at CDC Innovation from 2000 to 2003 and at AGF Private Equity (now Idinvest Partners) from 2003 to 2010, where he was in charge of developing the life sciences investment activity. During this period, Rémi served on the board of several investee companies such as Adocia, Bioalliance Pharma (listed on Euronext), Domain Therapeutics, Integragen (listed on Alternext), Novagali Pharma (listed on Euronext), Prosensa and Zealand Pharma (listed on Nasdaq OMX Copenhagen).

Remi has an MSc in molecular biology (Paris VI University) and an MSc in finance and innovation management (Masternova – AgroPariTech).

Joël is managing partner and co-founder of Ysios Capital. Previously, he co-founded Glycart Biotechnology AG in 2001 and was its CEO until the company was successfully sold to F. Hoffmann La-Roche in 2005. Joël is currently on the Boards of Aura Biosciences Inc, Medlumics S.A., Sanifit S.L., Dermalumics S.L. and Chairman of Inbiomotion S.L. He has been Chairman of the board of Cellerix (now Tigenix NYSE Euronext TIG) and Board Observer at Boston-based Biovex Inc. (now Amgen). He has earned numerous awards, including the Wall Street Journal Europe Innovation Award in 2001. Joël holds a masters degree in Biotechnology and earned his PhD from the Swiss Federal Institute of Technology (ETH) in Zurich.

Rita Jain, M.D., Former Senior Vice President and Chief Medical Officer, Akebia Therapeutics, joined our Supervisory Board since April 2020. She is also a member of the Board of Directors for Chemocentryx. Previously, Dr. Jain served as the Senior Vice President and Chief Medical Officer of Akebia Therapeutics, Inc and had management roles at AbbVie, Inc and prior to the split of AbbVie from Abbott, at Abbott Laboratories. Most recently, as Vice President of Men’s and Women’s Health and Metabolic Development at AbbVie, Inc., and she held various positions including Divisional Vice President at Abbott Laboratories. Dr. Jain also led activities in pain, respiratory, cystic fibrosis development, arthritis, inflammation and pain. Dr. Jain was a faculty member at North Shore University Hospital in New York, with an academic appointment as Assistant Professor of Medicine, New York University School of Medicine.

Dr. Jain received her B.S. in biology from LIU/C.W. Post and her M.D. from the State University of New York at Stony Brook School of Medicine. Dr. Jain completed her medical training in internal medicine at Staten Island University Hospital followed by a Fellowship in Rheumatology at North Shore University Hospital and a Clinical Research Fellowship at the University of Texas Southwestern Medical Center, Dallas.

Prior to joining AM-Pharma’s Supervisory Board, Mark Altmeyer was founder, President and Chief Executive Officer at Arvelle Therapeutics, in addition to serving as Executive Director of Arvelle’s Board of Directors. At Arvelle, he led the development of the company until its acquisition by Angelini for USD 1 billion. In advance of that transaction, he established Arvelle’s global headquarters in Switzerland, secured USD 200 million initial funding and built the European team to over 100 employees in under two years. Before Arvelle, Mark served as President and Chief Commercial Officer at Axovant Sciences, where he was responsible for establishing Axovant’s global commercial capabilities and launch preparations for various pipeline products. Earlier in his career, Mark served as President and CEO at Otsuka America Pharmaceutical, leading the transformation into a successful commercial organization, doubling total revenues from USD 2.5 billion to nearly 5 billion in five years. Mark held senior commercial and business development positions at Bristol-Myers Squibb, Cetus Corporation and Bristol Labs in the United States. He holds an MBA from Harvard Graduate School of Business and a BA in economics from Middlebury College.